Literature DB >> 9224705

Triabodies: single chain Fv fragments without a linker form trivalent trimers.

P Iliades1, A A Kortt, P J Hudson.   

Abstract

A single chain Fv fragment (scFv) of the murine monoclonal antibody 11-1G10 was constructed by directly joining the C-terminal residue of the V(H) domain to the N-terminal residue of V(L). 11-1G10 is an anti-idiotype and competes with the antigen, influenza virus neuraminidase (NA), for binding to the NC41 antibody. The scFv formed stable trimers with three active antigen combining sites for NC41 Fab fragments. We propose that trimeric scFvs may be the preferred conformation for directly linked V(H)-V(L) molecules, which contrasts the formation of scFv dimers (diabodies) when the V(H) and V(L) domains are joined by short flexible linkers of between 5-10 residues. BIAcore biosensor binding experiments showed that the trimeric scFv showed an expected increase in binding affinity, due to avidity, compared to the monomeric 15-residue linked scFv. The increase in avidity of scFv trimers offers advantages for imaging and immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9224705     DOI: 10.1016/s0014-5793(97)00475-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

1.  Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody.

Authors:  Barbara E Power; Larissa Doughty; Deborah R Shapira; John E Burns; Ann M Bayly; Joanne M Caine; Zhanqi Liu; Andrew M Scott; Peter J Hudson; Alexander A Kortt
Journal:  Protein Sci       Date:  2003-04       Impact factor: 6.725

2.  Chemically self-assembled antibody nanorings (CSANs): design and characterization of an anti-CD3 IgM biomimetic.

Authors:  Qing Li; Christopher R So; Adrian Fegan; Vivian Cody; Mehmet Sarikaya; Daniel A Vallera; Carston R Wagner
Journal:  J Am Chem Soc       Date:  2010-11-15       Impact factor: 15.419

Review 3.  Continuing pursuit for ideal systemic anticancer radiotherapeutics.

Authors:  Marlein Miranda Cona; Huaijun Wang; Junjie Li; Yuanbo Feng; Feng Chen; Peter de Witte; Alfons Verbruggen; Yicheng Ni
Journal:  Invest New Drugs       Date:  2011-10-18       Impact factor: 3.850

4.  Oligomeric forms of single chain immunoglobulin (scIgG).

Authors:  Thomas Schirrmann; Christian Menzel; Michael Hust; Jessica Prilop; Thomas Jostock; Stefan Dübel
Journal:  MAbs       Date:  2010-01-26       Impact factor: 5.857

5.  Engineering tandem single-chain Fv as cell surface reporters with enhanced properties of fluorescence detection.

Authors:  Eugenio Gallo; Avin C Snyder; Jonathan W Jarvik
Journal:  Protein Eng Des Sel       Date:  2015-04-05       Impact factor: 1.650

6.  The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments - A modular transition from full-length immunoglobulins to antibody mimetics.

Authors:  Sami El Khatib; Mohamed Salla
Journal:  Leuk Res Rep       Date:  2022-06-27

7.  Engineering peptide linkers for scFv immunosensors.

Authors:  Zhihong Shen; Heping Yan; Ying Zhang; Raymond L Mernaugh; Xiangqun Zeng
Journal:  Anal Chem       Date:  2008-02-22       Impact factor: 6.986

8.  Modulating Antibody Structure and Function through Directed Mutations and Chemical Rescue.

Authors:  Christine E Kaiser; Juan Pablo Rincon Pabon; Jittasak Khowsathit; M Paola Castaldi; Steven L Kazmirski; David D Weis; Andrew X Zhang; John Karanicolas
Journal:  ACS Synth Biol       Date:  2018-04-09       Impact factor: 5.110

9.  Single chain Fab (scFab) fragment.

Authors:  Michael Hust; Thomas Jostock; Christian Menzel; Bernd Voedisch; Anja Mohr; Mariam Brenneis; Martina I Kirsch; Doris Meier; Stefan Dübel
Journal:  BMC Biotechnol       Date:  2007-03-08       Impact factor: 2.563

Review 10.  Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments.

Authors:  Annamaria Sandomenico; Jwala P Sivaccumar; Menotti Ruvo
Journal:  Int J Mol Sci       Date:  2020-08-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.